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Original Article Partial agonism improves the anti-
hyperglycaemic efficacy of an oxyntomodulin-
derived GLP-1R/GCGR co-agonist Phil Pickford 1, Maria Lucey 1, Roxana-Maria Rujan 2, Emma Rose McGlone 1, Stavroula Bitsi 3, 
Fiona B. Ashford 4,5, Ivan R. Corrêa 6, David J. Hodson 4,5, Alejandra Tomas 3, Giuseppe Deganutti 2, 
Christopher A. Reynolds 2,7, Bryn M. Owen 1, Tricia M. Tan 1, James Minnion 1, Ben Jones 1,* , 
Stephen R. Bloom 1 ABSTRACT 
Objective: Glucagon-like peptide-1 and glucagon receptor (GLP-1R/GCGR) co-agonism can maximise weight loss and improve glycaemic control 
in type 2 diabetes and obesity. In this study, we investigated the cellular and metabolic effects of modulating the balance between G protein and 
b-arrestin-2 recruitment at GLP-1R and GCGR using oxyntomodulin (OXM)-derived co-agonists. This strategy has been previously shown to 
improve the duration of action of GLP-1R mono-agonists by reducing target desensitisation and downregulation. 
Methods: Dipeptidyl dipeptidase-4 (DPP-4)-resistant OXM analogues were generated and assessed for a variety of cellular readouts. Molecular 
dynamic simulations were used to gain insights into the molecular interactions involved. In vivo studies were performed in mice to identify the 
effects on glucose homeostasis and weight loss. 
Results: Ligand-specific reductions in b-arrestin-2 recruitment were associated with slower GLP-1R internalisation and prolonged glucose-
lowering action in vivo. The putative benefits of GCGR agonism were retained, with equivalent weight loss compared to the GLP-1R mono-
agonist liraglutide despite a lesser degree of food intake suppression. The compounds tested showed only a minor degree of biased agonism 
between G protein and b-arrestin-2 recruitment at both receptors and were best classified as partial agonists for the two pathways measured. 
Conclusions: Diminishing b-arrestin-2 recruitment may be an effective way to increase the therapeutic efficacy of GLP-1R/GCGR co-agonists. 
These benefits can be achieved by partial rather than biased agonism. 
 2021 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 
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Insulin and glucagon are traditionally viewed as opposing protagonists 
in the hormonal control of blood glucose. Pharmacological approaches 
to potentiate glucose-stimulated insulin secretion (GSIS), such as 
analogues of the incretin glucagon-like pepide-1 (GLP-1), have been 
successfully exploited over many years to treat type 2 diabetes (T2D) 
[1]. However, decades of attempts to develop glucagon receptor 
(GCGR) antagonists for clinical use have thus far failed to yield any 
approved therapeutic agents [2]. A significant problem appears to be 
the development of hepatic steatosis [3e6]. Contrasting with this 
traditional approach, GCGR agonism has emerged as a credible 
component of combined therapeutic strategies for treating obesity and 
T2D in which GLP-1R and GCGR are concurrently targeted [7,8], 
thereby recapitulating the effects of the endogenous GLP-1R/GCGR co-   
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www.molecularmetabolism.com agonist oxyntomodulin (OXM) [9]. Well-established effects of glucagon 
on energy expenditure [10] leading to enhanced weight loss and ul-
timately improvements in insulin sensitivity [11] might be safely 
realised in the context of GLP-1R-mediated protection against acute 
hyperglycaemia. Glucagon is also insulinotropic, an effect that derives 
from action at both GLP-1R and GCGR [12,13]. 
Biased agonism is a concept in which different ligands for the same 
receptor selectively couple to different intracellular effectors [14], 
potentially providing a method of improving their therapeutic window 
by reducing the activation of pathways associated with adverse effects 
[15]. For G protein-coupled receptors (GPCRs), bias is commonly but 
not always expressed as a relative preference for recruitment of G 
proteins vs b-arrestins, that is, two of the most proximal interactors 
recruited to the activated receptor as well as their corresponding 
signalling intermediates. Both GLP-1R and GCGR are primarily coupled  
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Abbreviations 
AIB 2-aminoisobutyric acid 
barr b-arrestin 
cAMP Cyclic adenosine monophosphate 
DERET Diffusion-enhanced resonance energy transfer 
DPP-4 Dipeptidyl dipeptidase-4 
ECL Extracellular loop 
GCG(R) Glucagon (receptor) 
GIP(R) Glucose-dependent insulinotropic polypeptide (receptor) 
GLP-1(R) Glucagon-like peptide-1 (receptor) 
HCA High content analysis 
IPGTT Intraperitoneal glucose tolerance test 
OXM Oxyntomodulin 
PKA Protein kinase A 
T2D Type 2 diabetes 
TM Transmembrane (helix) to cAMP generation through Gas activation, with recruitment of b-
arrestins being associated with receptor desensitisation, endocytosis, 
and diminished long-term functional responses [16,17]. While the 
therapeutic benefits of biased GLP-1R agonism have been demon-
strated in a number of preclinical studies [18e21], applying this 
principle to GLP-1R/GCGR co-agonism has been less explored. A 
recent study reported bias profiles for a selection of investigational dual 
GLP-1R/GCGR agonists, but it is not clear what role bias plays in their 
metabolic effects [22]. 
In this study, we aimed to develop GLP-1R/GCGR co-agonists with 
altered signalling properties but otherwise equivalent characteristics, 
which might be used to assess the functional impact of bias in vitro and 
in vivo. Focussing on the peptide N-terminus, we evaluated dipeptidyl 
dipeptidase-4 (DPP-4)-resistant peptides featuring 2-aminoisobutyric 
acid (AIB) at position 2 in combination with which a switch between 
glutamine (Q) and histidine (H) at position 3 was able to alter the 
maximum responses (that is, efficacy) for G protein and b-arrestin 
recruitment to varying degrees at both receptors. Molecular dynamics 
simulation of glucagon analogues interacting with GCGR was used to 
gain insight into the molecular interactions underlying these differences. 
By comparing the metabolic effects of a pair of matched peptides with 
these sequence substitutions, we demonstrate that reduced recruitment 
efficacy of b-arrestins translates into improved efficacy in preclinical 
rodent models of obesity, consistent with a similar effect previously 
observed for GLP-1R mono-agonists [18e21]. Our study therefore 
suggests a viable strategy to optimise GLP-1R/GCGR co-agonism for 
enhanced therapeutic efficacy. 
2. MATERIALS AND METHODS 
2.1. Peptides 
All of the peptides were obtained from Wuxi Apptec and were at least 
90% pure. 
2.2. Cell culture 
HEK293T cells were maintained in DMEM supplemented with 10% 
FBS and 1% penicillin/streptomycin. PathHunter CHOeK1-barr2-EA 
cells stably expressing human GLP-1R, GCGR, or GIPR and Path-
Hunter CHOeK1-barr1-EA cells stably expressing GCGR were obtained 
from DiscoverX and maintained in Ham’s F12 medium with 10% FBS 
and 1% penicillin/streptomycin. Stable HEK293-SNAP-GLP-1R cells MOLECULAR METABOLISM 51 (2021) 101242  2021 The Authors. Published by Elsevier G2  
 
 
[23] were maintained in DMEM supplemented with 10% FBS, 1% 
penicillin/streptomycin, and 1 mg/ml of G418. INS-1 832/3 cells, a gift 
from Professor Chris Newgard (Duke University) [24], were maintained 
in RPMI with 11 mM of glucose supplemented with 10% FBS, 10 mM 
of HEPES, 1 mM of pyruvate, 50 mM of  b-mercaptoethanol, and 1% 
penicillin/streptomycin. Huh7 cells stably expressing human GCGR 
(Huh7-GCGR) [25] were maintained in DMEM supplemented with 10% 
FBS, 1 mg/ml of G418, and 1% penicillin/streptomycin. 
2.3. Animal husbandry 
The animals were maintained in specific pathogen-free facilities, with 
ad libitum access to food (except prior to fasting studies) and water. 
The studies were regulated by the UK Animals (Scientific Procedures) 
Act 1986 of the UK and approved by the Animal Welfare and Ethical 
Review Body of Imperial College London (Personal Project License 
PB7CFFE7A) or the University of Birmingham (Personal Project License 
P2ABC3A83). Specific procedures are described as follows. 
2.4. Primary islet isolation and culture 
The mice were euthanised by cervical dislocation before injection of 
collagenase solution (1 mg/ml of Serva NB8 or S1745602, Nordmark 
Biochemicals) into the bile duct. Dissected pancreata were then 
digested for 12 min at 37 C in a water bath before purification of islets 
using a Ficoll (1.078) or Histopaque (Histopaque-1119 and -1083) 
gradient. Islets were hand-picked and cultured (5% CO2, 37 C) in 
RPMI medium containing 10% FBS and 1% penicillin/streptomycin. 
2.5. Primary hepatocyte isolation and culture 
Hepatocytes from adult male C57Bl/6J mice were isolated using 
collagenase perfusion [26]. After filtering and washing, the cells were 
used to directly assay cAMP responses as described in the next 
section. 
2.6. NanoBiT assays and calculation of bias between mini-Gs and 
b-arrestin-2 
The assay was performed as previously described [21]. HEK293T cells 
in 12-well plates were transfected with 0.5 mg of GLP-1R-SmBiT plus 
0.5 mg of LgBiT-mini-Gs, -mini-Gi, or -mini-Gq [27] (gifts from Pro-
fessor Nevin Lambert, Medical College of Georgia) or 0.05 mg of GLP-
1R-SmBiT and 0.05 mg of LgBiT-b-arrestin-2 (Promega) plus 0.9 mg of  
pcDNA3.1 for 24 h. The cells were detached with EDTA, resuspended 
in HBSS, and furimazine (Promega) was added at a 1:50 dilution from 
the manufacturer’s pre-prepared stock. After dispensing into 96-well 
white plates, a baseline read of the luminescent signals was serially 
recorded for 5 min using a FlexStation 3 instrument at 37 C before the 
indicated concentration of ligand was added, after which the signals 
were repeatedly recorded for 30 min. For AUC analysis, the results 
were expressed relative to the individual well baseline for AUC cal-
culations over the 30-min stimulation period. Baseline drift over time 
frequently led to a negative AUC for vehicle treatment, which was 
subtracted from all of the results before construction of 3-parameter 
curve fits of the concentration-response using Prism 8.0. Bias was 
calculated using two approaches. First, the log max/EC50 method [28] 
was used, with the ratio of Emax to EC50 from 3-parameter fits for 
each ligand used to quantify agonism. After log10 transformation, 
responses were expressed relative to the reference agonist on a per 
assay basis to obtain Dlog(Emax/EC50) for each pathway. Pathway-
specific values were then expressed relative to each other to obtain 
DDlog(Emax/EC50), that is, the log bias factor. Second, a method 
derived from kinetic curve fitting was used [29]. Here, kinetic re-







each time point to the vehicle response prior to curve fitting. Mini-Gs 
responses were fitted using the one-phase exponential association 
equation in Prism 8.0. b-arrestin-2 responses were fitted using the 
biexponential equation described in [29]. The agonist efficacy term ks 
was derived from these data as described [29] for each agonist and, 
after log10 transform, the SRB103Q response was expressed relative 
to SRB103H as the reference agonist on a per assay basis to obtain 
Dlog ks. Pathway-specific values were then expressed relative to each 
other to obtain DDlog ks, that is, the log bias factor. 
2.7. Biochemical measurement of cAMP production 
PathHunter cells were stimulated with the indicated concentration of 
agonist for 30 min at 37 C in serum-free medium without phos-
phodiesterase inhibitors. INS-1 832/3 cells were stimulated with the 
indicated concentration of agonist for 10 min at 37 C in serum-free 
medium with 100 mM of 3-isobutyl-1-methylxanthine (IBMX). Pri-
mary dispersed mouse islet cells prepared by triturating intact islets in 
0.05% trypsin/EDTA for 3 min at 37 C were stimulated with the 
indicated concentration of agonist for 5 min at 37 C in serum-free 
medium with 11 mM of glucose and 500 mM of IBMX. Primary 
mouse hepatocytes were stimulated in serum-free medium with 
100 mM of IBMX for 10 min or 16 h in serum-free medium with 
100 mM of IBMX added for the final 10 min of incubation. Huh7-GCGR 
cells were stimulated in serum-free medium without phosphodies-
terase inhibitors for 10 min or for 16 h in serum-free medium. Where 
relevant, forskolin (10 mM) was added as a positive or normalisation 
control. At the end of each incubation, cAMP was then assayed by 
HTRF (Cisbio cAMP Dynamic 2) and concentration-response curves 
were constructed with 3-parameter curve fitting using Prism 8.0. 
2.8. Dynamic cAMP imaging in intact islets 
C57Bl/6 (n ¼ 7) or Ins1tm1.1(cre)Thorþ/- (n ¼ 2) mice were used as 
islet donors and were phenotypically indistinguishable. Islets were 
transduced with epac2-camps for 48 h using an adenoviral vector (a gift 
from Professor Dermot M. Cooper, University of Cambridge). Epac2-
camps is well validated, relatively pH insensitive, and senses cAMP 
concentrations in the ranges described in islets [30,31]. Dynamic cAMP 
imaging was performed as previously described [32] using a Crest X-
Light spinning disk system coupled to a Nikon Ti-E microscope base 
and a 10 objective. Excitation was delivered at l ¼ 430e450 nm 
using a SPECTRA X light engine. Emitted signals were detected using a 
16-bit Photometrics Evolve Delta EM-CCD at l ¼ 460e500 nm and 
520e550 nm for cerulean and citrine, respectively. For imaging, islets 
were maintained in HEPES-bicarbonate buffer (pH 7.4) containing (in 
mM): 120 NaCl, 4.8 KCl, 24 NaHCO3, 0.5 Na2HPO4, 5 HEPES, 2.5 
CaCl2, 1.2 MgCl2, and 16.7 D-glucose. The experiment was conducted 
to determine responses to agonist-naïve islets (“acute”) or with a 
“rechallenge” design in which islets were first treated for 4 h with 
100 nM of agonist followed by washout (2 washes for 30 min) before 
imaging. During imaging, the islets were stimulated with 100 nM of 
agonist for 15 min starting at T ¼ 5 min, followed by application of 
10 mM of forskolin as a positive control. FRET responses were calcu-
lated as the fluorescence ratio of cerulean/citrine and normalised as F/ 
F0-5, where F denotes the fluorescence at any given time point and F0-
5 denotes the average fluorescence for 0e5 min. 
2.9. High content imaging assay for receptor internalisation 
The assay was adapted from a previously described method [33]. 
HEK293T cells were seeded in black clear-bottom plates coated with 
0.1% poly-D-lysine and assayed 24 h after transfection with SNAP-









were labelled with the cleavable SNAP-tag probe BG-S-S-549 (a gift 
from New England Biolabs) in complete medium for 30 min at room 
temperature. After washing, fresh serum-free medium agonist was 
added. At the end of incubation, the medium was removed and the 
wells were treated with for 5 min at 4 C with Mesna (100 mM in 
alkaline TNE buffer at a pH of 8.6) to remove BG-S-S-549 
bound to residual surface receptors without affecting the internalised 
receptor population or with alkaline TNE buffer alone. After washing, 
phase contrast and epifluorescence cellular imaging at 20 
magnification was performed, followed by processing as previously 
described [33] to quantify the amount of internalised receptor from the 
fluorescence intensity readings. 
2.10. High content imaging for fluorescent ligand internalisation 
Huh7-GCGR cells were seeded in black clear-bottom plates coated 
with 0.1% poly-D-lysine and assayed 24 h later. Then 100 nM of 
fluorescent TMR-conjugated agonist or vehicle was applied for 30 min. 
The cells were then washed with cold HBSS and incubated for 5 min in 
cold acetic acid þ150 mM of NaCl buffer at a pH of 2.9 to strip surface 
ligands. After a final wash, the cells were resuspended in HBSS and 
the fluorescent ligand uptake was measured and quantified by high 
content imaging as described in Section 2.9. 
2.11. Imaging of fluorescent ligand uptake in pancreatic islets 
Mouse pancreatic islets were isolated and left to recover overnight 
before being immobilised with Matrigel onto glass-bottom Mattek 
dishes and stimulated with 100 nM of the indicated TMR-modified 
agonist for 30 min. Z stacks were recorded for the whole islet vol-
ume on a Zeiss LSM780 inverted confocal microscope with a 20 air 
objective and 1 mm of separation between optical slices. 
2.12. Preparing and imaging fixed cell samples to observe receptor 
internalisation 
Cells were seeded onto coverslips coated with 0.1% poly-D-lysine and 
assayed 24 h after transfection with SNAP-tagged GLP-1R or GCGR 
plasmid DNA (0.5 mg per well of a 24-well plate). Surface labelling of 
the SNAP-tagged GLP-1R was performed using 0.5 mM of the indicated 
SNAP-surface probe for 30 min at 37 C before washing with HBSS. 
Ligands were applied in Ham’s F12 media at 37 C. For fixation, 4% 
paraformaldehyde (PFA) was applied directly to the medium for 15 min 
before washing with PBS. Slides were mounted in Prolong Diamond 
antifade with DAPI and allowed to set overnight. Widefield epifluor-
escence imaging was performed using a Nikon Ti2E custom micro-
scope platform via a 100 1.45 NA oil immersion objective, followed by 
Richardson-Lucy deconvolution using DeconvolutionLab2 [34]. 
2.13. Measuring GLP-1R internalisation using DERET 
The assay was performed as previously described [21]. HEK-SNAP-
GLP-1R cells were labelled using 40 nM of SNAP-Lumi4-Tb in com-
plete medium for 60 min at room temperature. After washing, the cells 
were resuspended in HBSS containing 24 mM of  fluorescein and 
dispensed into 96-well white plates. A baseline read was serially 
recorded for 5 min using a FlexStation 3 instrument at 37 C in TR-
FRET mode using the following settings: lex at 340 nm, lem at 
520 and 620 nm, auto cut-off, delay of 400 ms, and integration time of 
1500 ms? Ligands were then added, after which the signals were 
repeatedly recorded for 30 min. The fluorescence signals were 
expressed ratiometrically after first subtracting signals from wells 
containing 24 mM of  fluorescein but no cells. Internalisation was 
quantified as the AUC relative to the individual well baseline, and 
concentration-response curves were generated with Prism 8.0. an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 3 




2.14. Insulin secretion assay 
INS-1 832/3 cells were seeded in suspension into complete medium 
with 11 mM of glucose agonist and incubated for 16 h at 37 C. 
Secreted insulin in the supernatant was analysed by HTRF (Insulin High 
Range kit, Cisbio) after dilution and normalised to the concentration in 
glucose-only treated wells. 
2.15. DPP-4 peptide degradation assay 
A total of 10 nmol of SRB103Q, SRB103H, or GLP-1 was dissolved in 
750 ml of DPP-4 buffer (100 mM of TriseHCl at a pH of 8). Then, 10 mU 
of recombinant DPP-4 (R&D Systems) or no enzyme as a control for 
non-enzymatic degradation over the same time period was added to the 
reconstituted peptide. Reactions were incubated at 37 C and 120 ml 
samples were collected from the reaction vessel at the indicated time 
points. Then, 5 ml of 10% trifluoroacetic acid (TFA) was added to each 
sample to terminate enzyme activity. The samples were analysed by 
reverse-phase high-performance liquid chromatography (HPLC) with a 
linear acetonitrile/water gradient acidified with 0.1% TFA on Phenom-
enex Aeris Peptide 3.6 mm XB-C18 columns (150 4.6 mm). The 
eluted peptides were detected at 214 nm. Peptide degradation was 
calculated by comparing the area under the peak of the original com-
pound with and without enzyme. 
2.16. In vivo studies 
Lean male C57Bl/6 mice (8e10 weeks of age with a body weight of 
25e30 g obtained from Charles River) were maintained at 21e23 C 
and 12-h lightedark cycles. Ad libitum access to water and normal 
chow (RM1, Special Diet Services) or diet containing 60% fat to induce 
obesity and glucose intolerance (D12492, Research Diets) for a min-
imum of 3 months before experiments was provided. The mice were 
housed in groups of 4, except for food intake assessments and the 
chronic administration study, when they were individually caged with 1 
week of acclimatisation prior to experiments. Treatments were 
randomly allocated to groups of mice matched for weight.  
2.17. Intraperitoneal glucose tolerance tests 
The mice were fasted for at least 4 h before commencing the glucose 
tolerance test depending on the peptide treatment length. Peptide or 
vehicle (0.9% saline) was injected into each mouse’s intraperitoneal (IP) 
cavity either 8 h before, 4 h before, or at the same time as the glucose 
challenge (acute). Glucose was dosed at 2 g/kg of body weight. Blood 
glucose levels were measured before a glucose challenge then at the 
times as indicated in the figure using a hand-held glucose meter 
(GlucoRx Nexus). Blood samples for insulin were collected at 10 min 
into lithium heparin-coated microvette tubes (Sarstedt, Germany), fol-
lowed by centrifugation (10,000 RPM for 8 min at 4 C) to separate the 
plasma. Plasma insulin was measured using a Cisbio mouse insulin 
HTRF kit. 
2.18. Insulin tolerance tests 
The mice were fasted for 2 h before IP injection of peptide or vehicle 
(0.9% saline). Four h later, baseline blood glucose was taken before 
recombinant human insulin (Sigma, USA) (0.5 U/kg-1 U/kg) was IP 
injected and blood glucose was measured 20, 40, and 60 min after 
insulin injection. 
2.19. Feeding studies 
The mice were fasted overnight before the study. Diet was returned to 
the cage 30 min after IP injection of agonist, with cumulative intake 
determined by weighing. MOLECULAR METABOLISM 51 (2021) 101242  2021 The Authors. Published by Elsevier G4  
 
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2.20. Pharmacokinetic study 
The mice were administered 0.5 mg/kg of peptide via IP injection. Four 
h after injection, blood was acquired by venesection into lithium 
heparin-coated microvette tubes (Sarstedt, Germany). In a separate 
study, male Sprague Dawley rats (average weight 250 g, obtained from 
Charles River) were administered 4 mg/kg of peptide SC mixed in 
aqueous ZnCl2 solution to a molar ratio of 0.7:1 (peptide:ZnCl2), and 
blood was collected by venesection at several time points up to 72 h. 
Plasma was separated by centrifugation at 10,000 g for 8 min at 4 C. 
Plasma concentrations were assessed by radioimmunoassay using an 
in-house assay as previously described [35] using standard curves 
generated from each SRB103 peptide to ensure that equivalent re-
covery was obtained. 
2.21. Chronic administration study 
SRB103 peptides were mixed in aqueous ZnCl2 solution to a molar ratio 
of 1.2:1 (ZnCl2:peptide). Liraglutide (Novo Nordisk) was diluted in sterile 
water. DIO mice received daily subcutaneous (s.c.) injections of each 
treatment or vehicle (matched ZnCl2) with the dose increased during 
the first week as indicated in the figure. Body weight and food intake 
was measured periodically, with food and water available ad libitum. 
The end-of-study glucose tolerance test was performed 8 h after the 
final peptide dose with the mice fasted for 5 h. Body composition was 
measured by EchoMRI at the end of the study. 
2.22. Statistical analysis of biological data 
Quantitative data were analysed using Prism 8.0 (GraphPad Software). 
In cell culture experiments, technical replicates were averaged so that 
each individual experiment was treated as one biological replicate. 
Dose responses were analysed using 3- or 4-parameter logistic fits 
with constraints imposed as appropriate. Bias analyses were per-
formed as described in Section 2.6. Statistical comparisons were 
made by t-tests or ANOVA as appropriate, with paired or matched 
designs used depending on the experimental design. Mean standard 
error of mean (SEM) with individual replicates in some cases are 
displayed throughout with the exception of bias analyses, for which 
95% confidence intervals are shown to allow straightforward identi-
fication of biased ligands, for which the 95% confidence bands did not 
cross zero. Statistical significance was inferred if p < 0.05 without 
ascribing additional levels of significance. 
2.23. Systems preparation, equilibration, and molecular dynamics 
simulation 
We performed molecular dynamics simulations on the active GCGR 
structure in complex with peptides GCG, GCG-AIB2, and GCG-AIB2H3 
and the C-terminal helix 5 of the Gs protein’s a-subunit. The struc-
ture was modelled using MODELLER software (https://salilab.org/ 
modeller) [36]. The templates used were the full-length crystal struc-
ture of a partially activated GCGR in complex with NNC1702 peptide 
(PDB: 5YQZ) [37] and the cryo-EM structure of the active glucagon-like 
peptide-1 receptor (GLP-1R) (PDB: 6B3J) [38]. Maestro software 
(https://www.schrodinger.com/) was employed to add the missing 
residue H1 and substitute the adequate residues to generate GCG, GCG-
AIB2, and GCG-AIB2H3. Once the three systems were complete 
and the hydrogens added, each system was embedded in a phos-
pholipidic membrane and solvated. The membrane model used was 1-
palmitoyl,2-oleoyl-sn-glycero-3-phosphochholine (POPC), which was 
generated by CHARMM-GUI (http://charmm-gui.org/). The simulation 
box dimensions of the resulting systems were 90 90 170 Å in the 
X, Y, and Z directions, respectively. General charge neutrality was 
obtained by adding Naþ and Cl-neutralising counter ions. Each system mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 
www.molecularmetabolism.com 
 
Table 1 e Amino acid sequences of the peptides used in this study. Amino 
acid sequences are given in single letter code. GLP-1 is amidated at the C-
terminus as indicated. AIB is represented as X. Tetramethylrhodamine is 
indicated as TMR. 










SRB103H-TMR HXHGTFTSDYSKYLDAKRAQEFIEWLLAGHHHHHPS(K-TMR)W was subjected to 10,000 cycles of energy minimisation to eliminate 
steric clashes and relax the side chains. The final step before running 
the simulations was represented by the equilibration of the systems, 
which included re-orientations of the water and lipid molecules around 
the protein. The systems were both equilibrated and simulated in an 
NVT ensemble with semi-isotropic pressure scaling with a constant 
surface tension dynamic of 0 dyne/cm (through interfaces in the XY 
plane). The target pressure of 1 bar was achieved using the Monte Carlo 
barostat, while the target temperature of 300 K was regulated using 
Langevin dynamics with a collision frequency of 1 ps-1. The SHAKE 
algorithm was used to constrain the lengths of bonds comprising 
hydrogen atoms. Each system was equilibrated for 32 ns at a time step 
of 2 fs and then run in 3 replicas for approximately 2 ms at a time step of 
4 fs using the AMBER force field implemented in the AMBER software 
package (http://ambermd.org/) [39]. 
2.24. MD trajectory analysis 
Each replica of a system was merged and aligned on the initial frame 
using MDTraj (www.mdtraj.org/) and then analysed. The hydrogen 
bonds and van der Waals interactions between peptides and receptors 
were computed using the GetContacts package (https://getcontacts. 
github.io/). The contacts were plotted on the PDB coordinates using 
in-house scripts and Chimera software (www.cgl.ucsf.edu/). The 
distances between T3696.60 located at the top of TM6 and the origin 
of the cartesian coordinates (0, 0, 0) were quantified using the open-
source community-developed library PLUMED 2.0 (www.plumed.org). 
Using the data provided by PLUMED, we further calculated the dis-
tances’ distribution via an in-house script. Principal component anal-
ysis (PCA) was conducted on Ca atoms using the R package Bio3D 
(www.thegrantlab.org/) [40]. Prior to PCA, we carried out a trajectory 
frame superposition on Ca atoms of residues 133 to 403 (TM domain) 
to minimise the root mean square differences among the equivalent 
residues. The principal component 1 (PC1) graphic representation was 
displayed through the Pymol Molecular Graphics System (https:// 
pymol.org/). 
3. RESULTS 
3.1. Characterising N-terminal peptide substitutions that modulate 
coupling to Gas and b-arrestin-2 at GLP-1R and GCGR 
The N-termini of GLP-1, glucagon, and OXM play critical roles in 
activating their target receptors [33,41]. However, alanine (in GLP-1) or 
serine (in glucagon and OXM) at position 2 renders each of these 
endogenous ligands susceptible to DPP-4-mediated cleavage, and 
pharmacologically stabilised incretin analogues are often modified at 
this position. In this study, we focussed on the AIB2 substitution found 
in semaglutide and some investigational oxyntomodulin analogues 
[42e44]. To systematically investigate how this change affects re-
ceptor activation, we obtained GLP-1-AIB2 and glucagon-AIB2 (GCG-
AIB2) (see Table 1) and measured recruitment of b-arrestin-2 and 
mini-Gs to GLP-1R and GCGR in real time using nanoBiT comple-
mentation [27,45]. Area-under-curve (AUC) quantification from the 
kinetic response data indicated that efficacy for b-arrestin-2 recruit-
ment to GLP-1R was modestly reduced with GLP-1-AIB2 compared to 
native GLP-1 (Table 2, Figure 1A, and Supplementary Fig. 1A). How-
ever, quantifying bias using the log(max/EC50) scale [28] indicated that 
this selective efficacy reduction did not qualify GLP-1-AIB2 as a biased 
agonist as it was compensated by a correspondingly small increase in 
potency (Figure 1B,C). The lack of bias is represented in Figure 1C by
the 95% confidence intervals for GLP-1-AIB2 crossing zero. At GCGR, 
the impact of AIB2 was more striking, with large reductions in efficacy MOLECULAR METABOLISM 51 (2021) 101242  2021 The Authors. Published by Elsevier GmbH. This is 
www.molecularmetabolism.com for both mini-Gs and b-arrestin-2 (Figure 1A); interestingly, this effect 
at GCGR could be partly reversed for both pathways by concurrent 
substitution of glutamine (Q) at position 3 to histidine (H), which our in-
house preliminary evaluations had already flagged as a route to 
modulate GCGR signalling. GCG-AIB2 showed a moderate but statis-
tically significant degree of bias in favour of mini-Gs recruitment, with 
the H3 substitution driving the bias factor back towards zero 
(Figure 1B,C). 
An alternative method for bias quantification has been proposed 
[29,46] that is applicable to scenarios when kinetic response data is 
available. This model-free approach quantifies efficacy, termed ks, 
from the initial response rate at a saturating agonist concentration. 
After logarithmic transformation of ks, bias can be determined by first 
normalising to a reference ligand (obtaining Dlog ks) and then 
comparing responses between pathways (obtaining DDlog ks). In our 
study, mini-Gs responses could be fitted as one-phase exponential 
association curves, whereas b-arrestin-2 showed a characteristic 
rapid increase and slower decline presumed to reflect b-arrestin as-
sociation followed by dissociation from the target receptor and required 
a bi-exponential equation to define the association and dissociation 
rate constants [47] (Figure 1D). GLP-1-AIB2 showed subtly slower 
kinetics at GLP-1R for both pathways than did GLP-1, which did not 
translate into a significant degree of bias using the DDlog ks method 
(Table 2 and Figure 1C). At GCGR, mini-Gs and b-arrestin-2 associ-
ation kinetics were also slower for GCG-AIB2 than glucagon (Figure 1D 
and Table 2), with bias assessment from the kinetic data again sug-
gesting a preference for mini-Gs coupling that was negated with the 
introduction of H3 (that is, less bias with GCG-AIB2H3 than GCG-AIB2; 
Figure 1C). 
Overall, these data indicate that introducing the AIB2 substitution into 
GLP-1 and glucagon led to a noticeable reduction in efficacy for b-
arrestin-2 recruitment, more than mini-Gs recruitment, with glucagon 
more affected than GLP-1. However, at GCGR, this effect could be 
mitigated by the presence of H3. The Q/H switch at position 3 thereby 
provides a method of modulating efficacy while retaining AIB2-induced 
resistance to DPP4. 
3.2. GCGR molecular dynamics simulations 
We performed molecular dynamics simulations of the active state GCGR 
in complex with glucagon, GCG-AIB2, or GCG-AIB2H3 to retrieve in-
sights into the effects that peptide mutations have on the interactions, 
fingerprints, and receptor flexibility. Substituting serine at position 2 
with the non-standard residue AIB produced a substantial loss of in-
teractions with the top of transmembrane helix 6 (TM6) and TM7 an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 5 
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Table 2 e Effect of AIB2 substitution in GLP-1, glucagon, or OXM on mini-Gs and b-arrestin-2 recruitment responses. Mean SEM parameter estimates from 
3-parameter fitting of AUC data from Figure 1A and association rate constants at maximal agonist stimulation (K@[max]). Statistical comparisons performed by 
paired t-tests (GLP-1 and GLP-1-AIB2) or randomised block one-way ANOVA with Dunnett s test (glucagon analogues). Note that, in general, if > 1 ligand was a 
full agonist, Emax values were compared after normalisation to the globally fitted maximum response, whereas if only one ligand was a full agonist, statistical 
comparison was performed prior to normalisation, but the numerical results are presented after normalisation to the full agonist response. See Supplementary 
Fig. 1 for further analysis of b-arrestin-2 recruitment using a different system. *p < 0.05 indicated by the statistical test. 
GLP-1R 
Mini-Gs b-arrestin-2 
pEC50 (M) Emax (% max) K@[max] (min-1) pEC50 (M) Emax (% max) K@[max] (min-1) 
GLP-1 7.7 0.1 105 2  0.30  0.04 7.3 0.2 100 0 1.25 0.31 
GLP-1-AIB2 7.9 0.0 96 2  0.21  0.01* 7.7 0.1* 68 4* 0.82 0.10 
GCGR 
Mini-Gs b-arrestin-2 
pEC50 (M) Emax (% max) K@[max] (min-1) pEC50 (M) Emax (% max) K@[max] (min-1) 
GCG 6.7 0.0 100 0  0.17  0.03 6.1 0.1 100 0 0.89 0.18 
GCG-AIB2 6.7 0.1 54 4* 0.11 0.01 6.2 0.1 25 2* 0.29 0.03* 
GCG-H3 6.8 0.1 66 5* 0.13 0.04 6.3 0.1 54 6* 0.51 0.06* 
GCG-AIB2H3 7.0 0.1* 74 5* 0.13 0.01 6.6 0.1* 53 2* 0.56 0.06* (E3626.53, F3656.56, and D3857.42 in Figure 2A,B). Fewer contacts 
were also formed with TM3 (I2353.40 and Y2393.44) and TM5 
(W3045.36) compared to glucagon. Substituting S2 with the hydro-
phobic AIB removed a persistent hydrogen bond with a D3857.42 side 
chain (Table 3) and moved the barycentre of the interactions towards 
extracellular loop 2 (ECL2) (D299ECL2 and S297ECL2 in Figure 2A,B) 
due to hydrogen bonds with H1 and T5 (Table 3). The partial release of 
TM6 from the restraining interactions with the peptide N-termini was 
corroborated by the high flexibility displayed in Figure 2C. GCGR in 
complex with glucagon and AIB2H3, on the other hand, was charac-
terised by low plasticity of TM6 as indicated by monodisperse proba-
bility curves. Overall, glucagon and GCG-AIB2 stabilised divergent GCGR 
conformations of TM6, ECL2, and ECL3 (Figure 2D). Interestingly, in the 
closely related GLP-1R, ECL2 is essential for transducing peptide-
receptor interactions into cAMP accumulation, while a possible corre-
lation between peptides more prone to interact with ECL3 and b-
arrestin-influenced signalling events such as ERK1/2 phosphorylation 
has been proposed, for example, for oxyntomodulin, exendin-4 and P5 
[38,48]. Significantly, recently described structures of GLP-1R com-
plexed with semaglutide or taspoglutide that contain the AIB2 substi-
tution also highlight divergence in the conformation of ECL3 compared 
to GLP-1 [49]. Moreover, a recent GCGR structural study identified 
distinct ECL3 conformations stabilised by glucagon and P15, a GLP-1R/ 
GCGR co-agonist peptide [50]. 
The simulations suggested that the Q3H mutation introduced in GCG-
AIB2H3 favoured interactions between the peptide and TM2 residues 
K1872.60, V1912.64, and Q1311.29 located on the receptor’s stalk 
region. K1872.60 in particular is part of the conserved hydrophilic 
region within class B receptor TMD implied in binding, functionality, 
and signal transmission [51]. It is plausible that the recovery in efficacy 
displayed by GCG-AIB2H3 over AIB2 might be driven by stronger in-
teractions with TM2. Moreover, the whole TMD closed up around GCG-
AIB2H3 during the simulations, similar to GCG (Figure 2C,D). 
3.3. Pharmacologically stabilised GLP-1R/GCGR co-agonists to 
study the impact of efficacy variations 
A pair of peptides termed SRB103 (Table 1) was developed by an 
iterative process of sequence changes to the GLP-1R/GCGR co-agonist 
used in an earlier study [25]. As the previous peptide was derived 
from OXM, it contained the N-terminal sequence HeS-Q, which was MOLECULAR METABOLISM 51 (2021) 101242  2021 The Authors. Published by Elsevier G6 modified to H-AIB-Q (SRB103Q) or H-AIB-H (SRB103H) along with 
additional conservative changes to enhance physicochemical proper-
ties such as stability and solubility. As expected, both SRB103Q 
and SRB103H were highly resistant to DPP-4-mediated degradation 
(Supplementary Fig. 2A). 
The mini-Gs and b-arrestin-2 recruitment profiles of each ligand were 
compared at both GLP-1R and GCGR (Figure 3A, Table 4, and 
Supplementary Fig. 2B). At GLP-1R, AUC analysis from the kinetic 
response data indicated a 40% reduction in b-arrestin-2 efficacy but a 
small increase in potency for the AIB2Q3 ligand compared to AIB2H3, 
with the mini-Gs response unaffected. At GCGR, both potency and 
efficacy were significantly reduced in both pathways with the AIB2Q3 
ligand, although the magnitude of the efficacy reduction (w20%) was 
small compared to the same sequence substitutions when applied to 
glucagon in Figure 1. Using the log(max/EC50) method, there was no 
statistically significant bias between mini-Gs and b-arrestin-2 for 
SRB103Q vs SRB103H at either receptor (Figure 3B,C). However, bias 
estimates from the kinetic responses (DDlog ks method) suggested a 
subtle preference for SRB103Q at GLP-1R towards mini-Gs recruit-
ment (Figure 3C,D). As a role for Gaq signalling has been reported for 
GLP-1R in islets [52], and Gai-dependent signalling was shown to 
paradoxically increase GCGR-induced hepatic glucose output [53], we 
also compared each SRB103 ligand for its ability to promote mini-Gq 
and mini-Gi to GLP-1R and GCGR (Supplementary Figs. 2C and D). 
These responses were generally of considerably lower magnitude 
than for mini-Gs, suggesting that Gas dominates in this cell system. 
However, SRB103H appeared to induce greater coupling to mini-Gq 
and mini-Gi than SRB103Q to GCGR. 
The cAMP signalling responses were also assessed in CHOeK1 cell 
lines expressing GLP-1R, GCGR, or glucose-dependent insulinotropic 
polypeptide receptor (GIPR) (Figure 3E and Table 4). Unsurprisingly 
given the high degree of amplification seen in heterologous cell lines, 
reduced mini-Gs recruitment efficacy did not result in any reduction in 
cAMP Emax with SRB103Q, similar to a recent evaluation of GLP-1R/ 
GIPR co-agonists [54]. Potencies for SRB103Q and SRB103H were, as 
expected, indistinguishable at GLP-1R, with a non-significant reduction 
for SRB103Q at GCGR. Both ligands showed at least 100-fold reduced 
potency for GIPR cAMP signalling compared to GIP itself, even in this 
highly amplified heterologous system, suggesting that GIPR was un-
likely to contribute to their overall metabolic actions. mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 
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Figure 1: Evaluation of N-terminal substitutions to GLP-1, glucagon, or OXM. (A) Concentration responses with 3-parameter fits showing mini-Gs (mGs) or b-arrestin-2 (barr2) 
recruitment to GLP-1R-SmBiT or GCGR-SmBiT in HEK293T cells stimulated with GLP-1, GLP-1-AIB2, glucagon (GCG), GCG-AIB2, GCG-H3, or GCG-AIB2H3, n ¼ 5, with 3-parameter 
fits shown. (B) Heatmap representation of mean responses after quantification by log(max/EC50) or the ks method and normalisation to the reference ligand (GLP-1 or GCG, as 
appropriate). (C) Assessment of bias between mini-Gs and b-arrestin-2 recruitment from log(max/EC50) or the ks method, with statistical comparison by randomised block one-
way ANOVA with Sidak’s test comparing GCG-AIB2 and GCG-AIB2H3. The 95% confidence intervals are shown to allow identification of ligands with statistically significant bias vs 
the reference ligand. (D) Single maximal concentration kinetic responses of each ligand/receptor/pathway combination using the data shown in (A), with one-phase association fits 
for mini-Gs and bi-exponential fits for b-arrestin-2. *p < 0.05 indicated by the statistical test. Data are represented as mean   SEM for concentration response curves or 95% 
confidence intervals for bias plots; bias data are considered significant if the 95% confidence interval does not cross 0. A close correlation was previously observed between transducer 
coupling efficacy and ligand-induced endocytosis of GLP-1R [19,20]. 
GCGR, on the other hand, appears to internalise far more slowly 
[33,55]. We investigated the effects of SRB103Q and SRB103H on 
internalisation of GLP-1R and GCGR SNAP-tagged at their N-termini in 
HEK293T cells using high content imaging [33]. Both ligands induced 
pronounced GLP-1R internalisation, with a minor reduction in efficacy 
with SRB103Q, but GCGR barely internalised with either ligand 
(Figure 3F); higher resolution images of SNAP-GLP-1R- or SNAP-
GCGR-expressing cells labelled prior to agonist treatment corrobo-
rated these findings (Figure 3G). Interestingly, when measured by 
diffusion-enhanced resonance energy transfer (DERET) [56], kinetics of 
GLP-1R internalisation were considerably slower for SRB103Q than 
SRB103H throughout the concentration range (Figure 3H,I), although 
using AUC quantified from the end of the stimulation period, SRB103Q 
internalisation efficacy was only subtly reduced (Figure 3J), similar to 
the result in the high content imaging assay. 
These data indicate that the AIB2Q3 iteration of SRB103 showed 
reduced efficacy for recruitment of b-arrestin-2 at GLP-1R and, to a 
lesser degree, for mini-Gs and b-arrestin-2 at GCGR. MOLECULAR METABOLISM 51 (2021) 101242  2021 The Authors. Published by Elsevier GmbH. This is 
www.molecularmetabolism.com 3.4. Evaluating acute vs prolonged responses with SRB103H and 
SRB103Q 
Reductions in efficacy for b-arrestin-2 recruitment and endocytosis 
lead to prolongation of cAMP signalling at GLP-1R [19,41] and GCGR 
[33], which is thought to result from avoidance of target receptor 
desensitisation and/or downregulation. Interestingly, despite the ca-
nonical role of b-arrestins in promoting clathrin-mediated endocytosis, 
b-arrestin recruitment appears to be dispensable for GLP-1R inter-
nalisation [23,33], indicating that these phenomena may modulate 
signalling duration through distinct mechanisms. In both INS-1 832/3 
clonal beta cells [24] and dispersed mouse islet cells, biochemically 
measured acute cAMP responses to SRB103Q and SRB103H were 
indistinguishable (Figure 4A, B, and Table 4). However, SRB103Q 
showed greater potency than SRB103H for prolonged insulin secretion 
in INS-1 832/3 cells, amounting to, for example, an almost two-fold 
increase in insulin release at w1 nM agonist concentration 
(Figure 4C and Table 4). Of note, uptake in mouse islets of an SRB103Q 
analogue conjugated to tetramethylrhodamine (TMR) close to the C-
terminus (SRB103Q-TMR, Table 1) was somewhat reduced compared 
to SRB103H-TMR (Figure 4D) in keeping with the moderate differences an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 7 
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Figure 2: MD simulations of GCGR in complex with glucagon, GCG-AIB2, or GCG-AIB2H3. A and B show the difference in the contacts between GCGR and GCG-AIB2 (A) or GCG-
AIB2H3 (B) plotted on the ribbon representation of GCGR; residues in red were more engaged by GCG-AIB2 (A) or GCG-AIB2H3 (B), while blue residues formed more contacts with 
GCG. (C) Probability distribution of the distance between TM6 residue T369 and the origin of the cartesian coordinates (point 0, 0, 0). (D) Superposition of the PC1 analysis 
computed on the simulations of GCGR in complex with GCG (blue) or GCG-AIB2 (red). in GLP-1R endocytosis observed with this ligand in Figure 3. Addi-
tionally, FRET imaging of intact mouse islets virally transduced to 
express the cAMP sensor epac2-camps [57] demonstrated that both 
agonists acutely induced similar cAMP dynamics (Figure 4E), but when 
pre-treated for 4 h with each ligand and then rechallenged after a 
washout period, a trend towards reduced responsiveness for SRB103H 
was observed. This difference was not significant when quantified 
from the whole re-stimulation period, but it was clearly observed that 
the epac2-camps average signal increase on SRB103H rechallenge MOLECULAR METABOLISM 51 (2021) 101242  2021 The Authors. Published by Elsevier G8 was slower than for SRB103Q (k ¼ 0.28 vs 0.53 min-1 from pooled 
responses to SRB103H and SRB103Q, respectively), suggesting 
diminished responsiveness with the former ligand. 
We also assessed the potential for time-dependent differences in 
GCGR signalling. For islet cells, maximal acute cAMP responses in 
Huh7 hepatoma cells stably expressing GCGR [25] were indistin-
guishable, but a clear increase was seen with SRB103Q when the cells 
were incubated for 16 h (Figure 4F and Table 4). GCGR responses were 
also evaluated in primary mouse hepatocytes; SRB103Q showed mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 
www.molecularmetabolism.com 
Table 3 e Molecular dynamics simulation results. Hydrogen bonds 
between GCGR and the first five amino acids in GCG, GCG-AIB2, and GCG-
AIB2H3. Occupancy represents the number of frames with interactions 
divided by the total number of frames. ss indicates side chain-side chain 
hydrogen bonds, while sb indicates backbone-side chain hydrogen bonds. 
Peptide Ligand Receptor Occupancy Type of hydrogen 
residue residue (%) bond 
GCG H1 E3626.53 37.4 sb 
D3857.42 30.4 
S2 D3857.42 78.5 ss 
18.4 sb 
Q3 Y1451.43 20.5 ss 
Y1491.47 18.2 
T5 N298ECL2 10.6 sb 
GCG-AIB2 H1 D299ECL2 30.2 sb 
K1872.60 14.2 ss 
D3857.42 11.7 
AIB2 D3857.42 43.2 sb 
Q3 Y1491.47 35.1 ss 
S3897.46 13.6 
G4 T296ECL2 16.4 sb 
T5 D299ECL2 30.4 ss 
GCG- H1 D299ECL2 47.2 sb 
AIB2H3 K1872.60 2.46 ss 
N298ECL2 14.1 
AIB2 D3857.42 21.0 sb 
H3 Y1491.47 11.9 ss 
T5 D299ECL2 13.8 reduced potency acutely, but after overnight treatment, this difference 
disappeared (Figure 4G and Table 4). Interestingly, although SNAP-
GCGR endocytosis was barely detectable in HEK cells (see Figure 3), 
TMR-conjugated SRB103H and SRB103Q analogues were clearly 
taken up into punctate endosome-like structures in Huh7-GCGR cells, 
with greater uptake seen with the H3 ligand (Figure 4H). This apparent 
discrepancy between receptor and ligand internalisation might be 
explained by rapid dissociation of the endocytosed GCGR/agonist 
complex and subsequent recycling of the receptor to the plasma 
membrane. 
Overall, these studies indicate a general tendency for SRB103Q re-
sponses at both receptors to be relatively enhanced with longer 
stimulations, which is compatible with reduced b-arrestin-mediated 
desensitisation of this ligand compared to SRB103H. 3.5. Anti-hyperglycaemic responses were prolonged after a single 
dose of SRB103Q vs SRB103H in mice 
As GLP-1R agonists with reduced b-arrestin-2 recruitment efficacy 
and/or delayed endocytosis show progressive increases in anti-
hyperglycaemic efficacy over longer exposure periods [19,21,58], 
we aimed to establish if this therapeutic principle could also be applied 
to GLP-1R/GCGR co-agonism. Indeed, blood glucose concentrations 
during an intraperitoneal glucose tolerance test (IPGTT) in lean mice 
tended to be lower after a single administration of SRB103Q compared 
to SRB103H, with this difference enhanced by a longer agonist 
exposure time (Figure 5A). A similar pattern was seen at a range of 
agonist doses (Supplementary Fig. 3A) and in diet-induced obese (DIO) 
mice (Figure 5B). 
Both GLP-1R and GCGR agonism potentiate glucose-stimulated insulin 
secretion [12], but can also acutely enhance insulin-stimulated glucose 
disposal [11,59]. Plasma insulin concentrations measured 10 min into a 
4-h-delayed IPGTT were higher with SRB103Q than SRB103H treat-
ment, suggesting the former’s improved anti-hyperglycaemic efficacy is MOLECULAR METABOLISM 51 (2021) 101242  2021 The Authors. Published by Elsevier GmbH. This is 
www.molecularmetabolism.com likely to derive at least partly from action on beta cells (Figure 5C) in 
keeping with greater insulin release observed after prolonged stimu-
lation with SRB103Q in Figure 4. We also performed insulin tolerance 
tests (ITTs) 4 h after agonist administration to assess potential effects 
on insulin sensitivity (Figure 5D and  Supplementary Fig. 3B). While ITT 
interpretation was complicated by differences in baseline due to the 
prior agonist exposure period, neither absolute nor percentage re-
ductions in blood glucose levels were different between agonists. 
Appetite suppression was also assessed in lean and diet-induced obese 
mice. SRB103Q was more effective than SRB103H, particularly at later 
time points in the obese cohort (Figure 5E). Additional studies in lean 
rats confirmed that the anorectic effect of SRB103Q was greater than 
SRB103H over 72 h (Figure 5F). Plasma concentrations of each ligand 
were the same 4 h after a single dose in mice (Supplementary Fig. 3C), 
suggesting that the progressive divergence in physiological effects 
several hours after dosing was unlikely to be due to altered pharma-
cokinetics. Serial sampling in rats with peptide co-injected subcuta-
neously with zinc to slow absorption through depot formation also 
indicated no obvious difference in pharmacokinetics (Supplementary 
Fig. 3D). 
Overall, these results indicate that, despite showing lower acute effi-
cacy for intracellular effector recruitment at both GLP-1R and GCGR, 
SRB103Q showed greater bioactivity in mice than SRB103H. For gly-
caemic effects, this difference tended to become more apparent with 
time in keeping with the previously established principle that the 
metabolic advantages of biased GLP-1R agonists are temporally 
specific. 3.6. Improved anti-hyperglycaemic efficacy of SRB103Q was 
preserved with chronic administration 
GLP-1R/GCGR co-agonists may hold advantages over GLP-1R mono-
agonists for treating obesity and related metabolic diseases as their 
GCGR-mediated effects on energy expenditure can promote additional 
weight loss [35,60,61]. To determine if the apparent benefits of 
SRB103Q on glucose homeostasis revealed in single-dose studies are 
also maintained after repeated dosing, SRB103H, SRB103Q, and the 
GLP-1R mono-agonist liraglutide were administered at matched doses 
to DIO mice for 2 weeks. The dose was up-titrated over several days, 
analogous to typical practise in the clinic, as well as in preclinical 
studies of incretin receptor agonists [21,62]. As expected, all of the 
agonists led to a significant amount of weight loss compared to vehicle 
(Figure 6A). This was primarily due to fat mass loss, although inter-
estingly, a small amount of lean mass was lost with both SRB103 
peptides but not liraglutide (Figure 6B), which could result from the 
known effects of GCGR agonism on amino acid flux and muscle 
catabolism [63]. However, the trajectory for weight lowering differed 
for both dual GLP-1R/GCGR agonists compared to liraglutide, with the 
latter being more effective earlier in the study before reaching a 
plateau after one week, as commonly observed with GLP-1R mono-
agonists in rodents [64e66]. Importantly, weight loss with both dual 
agonists was achieved despite liraglutide being more effective at 
suppressing energy intake throughout the study (Figure 6C), sug-
gesting a contribution of increased energy expenditure [67]. Interest-
ingly, SRB103Q was moderately more effective for weight loss than 
SRB103H despite similar energy intake, raising the possibility that 
reduced GCGR desensitisation could have contributed to improved 
longer-term effects on energy expenditure. Both SRB103Q and 
SRB103H outperformed liraglutide in an IPGTT performed at the end of 
the study, with SRB103Q being the most effective at reducing the 
glucose excursion (Figure 6D). an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 9 
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Figure 3: Development of a DPP-4-resistant GLP-1R/GCGR co-agonist with variable efficacy for intracellular effectors. (A) Concentration responses with 3-parameter fits for 
SRB103H- and SRB103Q-induced recruitment of mini-Gs or b-arrestin-2 to GLP-1R-SmBiT or GCGR-SmBiT in HEK293T cells, n ¼ 6. (B) Heatmap representation of mean re-
sponses after quantification by log(max/EC50) or ks method and normalisation to SRB103H as the reference ligand. (C) Assessment of bias between mini-Gs and b-arrestin-2 
recruitment from log(max/EC50) or the ks method. The 95% confidence intervals are shown to allow identification of ligands with statistically significant bias vs the reference 
ligand SRB103H. (D) Single maximal concentration kinetic responses for each ligand/receptor/pathway combination using data shown in (A), with one-phase association fits for 
mini-Gs and bi-exponential fits for b-arrestin-2. (E) cAMP responses in PathHunter CHOeK1 cells stably expressing GLP-1R, GCGR, or GIPR, n ¼ 6, with 3-parameter fits shown. 
(F) SNAP-GLP-1R and SNAP-GCGR internalisation measured by high content analysis (HCA) in HEK293 cells, n ¼ 4, with 3-parameter fits shown. (G) Representative images from 
n ¼ 2 experiments showing endocytosis of SNAP-tagged receptors transiently expressed in HEK293 cells and treated with 100 nM of agonist for 30 min. Scale bars ¼ 8 mm. (H) 
SNAP-GLP-1R internalisation in HEK293-SNAP-GLP-1R cells, n ¼ 5, with one-phase association fits for ligand concentrations > 10 nM shown (expressed as log[agonist] in M). (I) 
The concentration dependency of internalisation kinetics from (H) is shown. (J) Concentration responses quantified from the average response during the last 3 time points from (H), 
with 3-parameter fits. Data are represented as mean   SEM for concentration response curves or 95% confidence intervals for bias plots; bias data are considered significant if the 
95% confidence interval does not cross 0. 
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Table 4 e Pharmacological evaluation of SRB103H3 vs SRB103. Mean SEM parameter estimates from 3-parameter fitting of data from Figures 3 and 4 and 
association rate constants for kinetic data where relevant. Statistical comparisons performed by paired t-tests comparing SRB103Q vs SRB103H. If both ligands 
were full agonists, Emax values are shown after re-fitting data normalised to the globally fitted maximum response. If only one ligand was a full agonist, 
statistical comparison was performed prior to normalisation, but the numerical results are presented after normalisation to the full agonist response. *p < 0.05 
indicated by the statistical test. 
SRB103H SRB103Q 
pEC50 (M) Emax K@[max] (min-1) pEC50 (M) Emax K@[max] (min-1) 
GLP-1R mini-Gs (HEK293T) 7.1 0.1 103 4 0.93 0.29 7.3 0.1 97 3 0.70 0.20* 
GLP-1R barr2 (HEK293T) 6.4 0.1 100 0.37 0.06 6.7 0.0* 60 2* 0.39 0.05 
GCGR mini-Gs (HEK293T) 8.1 0.1 100 0.14 0.01 7.7 0.1* 83 1* 0.13 0.01 
GCGR barr2 (HEK293T) 7.5 0.1 100 0.81 0.07 7.3 0.1* 77 2* 0.71 0.06* 
GLP-1R cAMP (CHOeK1) 9.5 0.1 99 4 n.c. 9.5 0.1 103 2 n.c. 
GCGR CAMP (CHOeK1) 9.6 0.2 107 5 n.c. 9.4 0.2 103 4 n.c. 
GIPR CAMP (CHOeK1) 7.6 0.2 101 5 n.c. 7.0 0.1* 92 9 n.c. 
DERET (HEK293-SNAP-GLP-1R) 7.7 0.2 3.0 0.1 0.14 0.02 7.7 0.2 2.7 0.2* 0.5 0.01* 
HCA assay (HEK293-SNAP-GLP-1R) 8.1 0.1 86 2 8.6 0.0* 79 3* 
INS-1 832/3 cAMP, 10 min 8.1 0.1 67 6 8.2 0.2 70 7 
Primary islet cells cAMP, 5 min 9.0 0.4 1.7 0.1 9.0 0.4 1.6 0.1 
INS-1 832/3 insulin secretion, 16 h 8.8 0.2 3.5 0.3 9.3 0.1* 3.4 0.4 
Huh7-GCGR cAMP, 10 min 10.5 0.2 27 4 10.8 0.2* 27 4 
Huh7-GCGR cAMP,16 h 9.6 0.2 173 11 9.7 0.2 284 38* 
cAMP 10 min (primary hepatocytes) 9.4 0.1 170 7 8.9 0.1* 175 12 
cAMP 16 h (primary hepatocytes) 7.6 0.1 206 7 7.5 0.0 200 6 4. DISCUSSION 
In this study, we carefully evaluated the effects on GLP-1R and GCGR 
activity of the AIB2 substitution commonly used to confer DPP-4 
resistance to therapeutic GLP-1R/GCGR peptide agonists. Depending 
on the peptide context, this substitution reduced efficacy for recruit-
ment of key intracellular effectors at both target receptors. Interest-
ingly, this effect was counteracted by substituting the neighbouring 
amino acid Q to H, providing a method to compare the impact of the 
resultant efficacy changes while retaining DPP-4 resistance. While the 
efficacy-reducing effect of AIB2 was most prominently observed with 
glucagon at GCGR, in the context of the SRB103 peptides, this effect 
was in fact greater at GLP-1R, specifically for b-arrestin-2 recruitment, 
although GCGR responses were also modestly reduced. The potential 
importance of this pharmacological finding was hinted at by studies in 
primary and clonal cell models of pancreatic beta cells (or islets) and 
liver, tissues in which these responses are chiefly driven by, respec-
tively, GLP-1R and GCGR, where we observed that the lower efficacy 
SRB103Q ligand showed at least a trend towards relatively enhanced 
signalling responses at both GLP-1R and GCGR over time. These ob-
servations support our in vivo findings that the improved anti-
hyperglycaemic performance of SRB103Q becomes more apparent 
at later time points after dosing, as was previously seen with GLP-1R 
mono-agonists with analogous signalling parameters [19]. 
This study was originally designed to assess the potential for biased 
agonism to improve therapeutic targeting of GLP-1R and GCGR. 
However, the magnitude of bias between SRB103Q and SRB103H as 
assessed by two validated models was relatively small. Interestingly, 
while biased agonism has recently attracted considerable attention, it 
has also been suggested that low intrinsic signalling efficacy, rather 
than biased agonism per se, is a viable alternative explanation for the 
improved performance of certain m opioid receptor agonists [68], a 
GPCR target usually considered highly tractable to biased agonism 
[69]. This possibility is reinforced by a lack of consistency between 
formal bias estimates obtained from different analytical approaches, 
which can lead to different conclusions from the same data [70]. With 
regard to the lower efficacy SRB103Q agonist in our study, signal MOLECULAR METABOLISM 51 (2021) 101242  2021 The Authors. Published by Elsevier GmbH. This is 
www.molecularmetabolism.com amplification downstream of Gas activation means full cAMP/PKA 
responses are still possible, so, in combination with reduced efficacy 
for b-arrestin recruitment, this could lead to reductions in desensiti-
sation over time and allow longer-lasting signalling responses. Thus, 
beneficial responses from partial agonism may be achieved irre-
spective of whether or not formally quantified bias is present. Further 
evaluations to establish whether partial agonism or bias is the most 
important factor will be required to settle this issue. 
AIB2 substitution at position 2 is one of a number of sequence mod-
ifications that have been trialled to obtain DPP-4 resistance for incretin 
receptor analogues. While exendin-4, the prototypical DPP-4 resistant 
GLP-1R mono-agonist, contains a glycine at position 2, GLP-1-G2 was 
recognised in early studies to show an unacceptable loss of signalling 
potency [71]; more recently, it was demonstrated that this is also 
associated with reduced efficacy for recruitment of both mini-Gs and 
b-arrestin-2 to GLP-1R [41]. AIB2 is better tolerated by GLP-1 than G2 
while retaining identical protection against DPP-4-mediated degra-
dation [71] and has been incorporated into the current leading GLP-1R 
mono-agonist semaglutide [72]. Our new data indicate that, in the 
context of native GLP-1, AIB2 leads to a significant reduction in efficacy 
for recruitment of b-arrestin-2 while barely affecting recruitment of 
mini-Gs. This effect is likely to be peptide-specific, as we did not 
observe similar reductions in b-arrestin recruitment by AIB2 containing 
semaglutide in a previous study [19]. Interestingly, in the present work, 
AIB2 led to marked attenuation of engagement of GCGR with intra-
cellular effectors by glucagon analogues, an effect that was previously 
hinted by the lower cAMP signalling potency with a glucagon analogue 
bearing AIB at positions 2 and 16 [73]. In the latter study, GCGR sig-
nalling was partly restored by conjugation to a fatty acid moiety, a well-
established strategy used primarily to extend peptide pharmacoki-
netics by promoting reversible binding to albumin but, in this case, also 
found to enhance receptor activation. In our study, we observed that 
switching Q to H at position 3 of glucagon was an alternative method of 
reversing the deleterious effect of AIB2 on GCGR signalling. It is not 
clear if these strategies are equivalent, as in Ward et al.‘s study [73], 
the signalling deficit seen with AIB2 was a reduction in cAMP potency, 
whereas in our study, efficacies for mini-Gs and b-arrestin-2 reduced an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 11 
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Figure 4: Acute vs prolonged responses in vitro with SRB103Q and SRB103H. (A) Acute cAMP signalling in INS-1 832/3 cells, 10 min stimulation with 100 mM of IBMX, n ¼ 5, 3-
parameter fits shown (biphasic fit for GCG). (B) Acute cAMP signalling in primary dispersed mouse islets, 5 min stimulation with 500 mM of IBMX, n ¼ 4, 3-parameter fits shown. 
(C) Cumulative insulin secretion from overnight stimulation of INS-1 832/3 cells, n ¼ 5, 3-parameter fits shown (biphasic fit for GCG). (D) TMR agonist uptake in intact mouse islets, 
representative of n ¼ 2 repeats, maximum intensity projections are shown. (E) Whole islet cAMP responses to stimulation with 100 nM of the indicated agonist acutely or after 4-h 
pre-treatment and washout measured by FRET with virally transduced epac2-camps. Quantification from 25 to 42 mouse islets per treatment (5e9 mice from at least 2 in-
dependent islet preparations). AUCs during the agonist exposure period (pre-forskolin [10 mM]) were quantified and compared by two-way ANOVA with Sidak’s test. Representative 
images are shown. (F) Acute (10 min) and sustained (16 h) cAMP accumulation in Huh7-GCGR cells expressed relative to 10 mM of forskolin response, n ¼ 6. (G) Acute (10 min) 
and sustained (16 h) cAMP accumulation in primary mouse hepatocytes, expressed relative to 10 mM of forskolin response, n ¼ 4. (H) TMR-ligand uptake in Huh7-GCGR cells, 
30 min stimulation at 100 nM, representative images from n ¼ 4 repeats with quantification as relative fluorescence units (RFU) and comparison by paired t-test. Data are 
represented as mean   SEM, with individual repeats in some cases. but potencies were unaffected. A recent evaluation of GLP-1R/GCGR 
co-agonists [22] showed that the GLP-1R/GCGR/GIPR “tri-agonist” 
(GLP-1R/GCGR/GIPR) peptide originally described by Finan et al. [74], 
which includes the N-terminal sequence H-AIB-Q, does indeed show 
reductions in b-arrestin recruitment efficacy to GLP-1R (modest) and 
GCGR (substantial) compared to the endogenous agonist without 
major loss in potency, broadly matching our observations with native 
ligand analogues and SRB103 peptides. Measured signalling potency, MOLECULAR METABOLISM 51 (2021) 101242  2021 The Authors. Published by Elsevier G12 especially in the context of significantly amplified responses, for 
example, cAMP, is driven to varying extents by both affinity and effi-
cacy, with our results highlighting how the standard approach to 
evaluating incretin receptor agonists in vitro using cAMP in heterolo-
gous systems, which tends to render all compounds full agonists, may 
be insufficient to adequately decipher ligand pharmacology [75]. 
Importantly, our study also provides structural insights into the 
importance of position 2 of glucagon peptide analogues, with mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 
www.molecularmetabolism.com 
Figure 5: Immediate and delayed responses to SRB103Q and SRB103H in mice. (A) Blood glucose results during intraperitoneal glucose tolerance tests (IPGTTs) performed in lean 
male C57Bl/6 mice (n ¼ 10/group) with 2 g/kg of glucose injected IP at the same time as, 4 h after, or 8 h after 10 nmol/kg of agonist injection. Time point and AUC comparisons 
both by repeated measures two-way ANOVA with Tukey’s test; only SRB103Q vs SRB103H comparisons are shown. (B) As in (A) but in diet-induced obese male C57Bl/6 mice. (C) 
Plasma insulin and blood glucose results in lean male C57Bl/6 mice (n ¼ 10/group) 10 min after 2 g/kg of IP glucose administration, concurrently with, 4 h after, or 8 h after 
10 nmol/kg of agonist injection. AUC comparisons by repeated measures two-way ANOVA with Tukey’s test; only SRB103Q vs SRB103H comparisons are shown. (D) Blood glucose 
during insulin tolerance test (0.75 U/kg of recombinant human insulin IP) performed 4 h after administration of 10 nmol/kg of agonist injection in lean male C57Bl/6 mice (n ¼ 8/ 
group). Percentage reduction from 0 to 15 min is shown and compared by one-way ANOVA with Tukey’s test; only SRB103Q vs SRB103H comparison is shown. (E) Food intake in 
overnight-fasted lean male C57Bl/6 mice (n ¼ 8/group) treated with 10 nmol/kg of indicated agonist. Time point comparisons both by repeated measures two-way ANOVA with 
Tukey’s test; only SRB103Q vs SRB103H comparisons are shown. (F) Food intake in overnight-fasted lean Sprague Dawley rats (n ¼ 6e7/group) treated with indicated agonist 
dose every 24 h. Time point comparisons both by repeated measures two-way ANOVA with Tukey’s test; only SRB103Q vs SRB103H comparisons are shown. *p < 0.05 indicated 
by the statistical test. Data are represented as mean   SEM with individual replicates where possible. molecular dynamics simulations indicating that the reduced b-
arrestin-2 recruitment associated with the AIB2 substitution was 
related to reduced engagement of ECL3, a region recently noted to be 
important for signalling divergence between AIB2-containing GLP-1R 
agonists including semaglutide or taspoglutide compared to GLP-1 
itself [49]. 
The most striking results in our study were observed from in vivo 
comparisons of SRB103Q and SRB103H. Here, the lower efficacy 
SRB103Q (at both GLP-1R and GCGR) peptide outperformed SRB103H MOLECULAR METABOLISM 51 (2021) 101242  2021 The Authors. Published by Elsevier GmbH. This is 
www.molecularmetabolism.com for its ability to lower blood glucose levels 4 and 8 h after a single 
injection despite apparently equivalent pharmacokinetics. While a 
formal pharmacokinetic study would be required to rule out subtle 
differences, the a priori expectation that the two ligands would show 
altered pharmacokinetics is low. These findings are reminiscent of 
observations with exendin-phe1, a GLP-1R mono-agonist with marked 
reductions in b-arrestin recruitment efficacy, which displayed better 
anti-hyperglycaemic effects and increased insulin secretion compared 
to exendin-4 in mice, with these differences being most obvious at an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 13 
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Figure 6: Repeated administration of SRB103Q and SRB103H. (A) Effect on body weight of daily administration by s.c. injection of SRB103Q, SRB103H, liraglutide, or vehicle on 
body weight in male diet-induced obese C57Bl/6 mice, n ¼ 10/group, with statistical comparisons between agonists by repeated measures two-way ANOVA with the HolmeSidak 
test. The injected daily dose is indicated above the graph. (B) Body composition analysis by EchoMRI performed at the end of the study, with changes from baseline compared 
between treatments by one-way ANOVA with the HolmeSidak test. (C) As in (A) but cumulative food intake. (D) IPGTT (2 g/kg of glucose) performed on day 15 of the study 8 h after 
agonist administration. Statistical comparisons by repeated measures two-way ANOVA with the HolmeSidak test (time points) or one-way ANOVA with the HolmeSidak test. 
*p < 0.05 indicated by the statistical test and colour-coded where applicable. Data are represented as mean   SEM with individual replicates where possible. later time points [19]. However, one of the challenges with our study 
was identifying whether the observed effects resulted from enhanced 
action primarily at GLP-1R or GCGR, as SRB103Q displayed reduced b-
arrestin-2 recruitment efficacy at both receptors, meaning that longer-
lasting signalling through avoidance of target desensitisation could 
apply in both cases. Receptor and/or ligand uptake studies also sug-
gested that endocytosis of both receptors was slower with SRB103Q. 
Overall, we favour a primarily GLP-1R-mediated mechanism for the 
observed physiological effects because 1) the selective reduction in b-
arrestin-2 recruitment with SRB103Q was larger at GLP-1R than at 
GCGR and 2) the effect was associated with increases in insulin release 
and supported by a trend towards reduced islet desensitisation in vitro. 
While glucagon can augment glucose-stimulated insulin secretion, this 
effect is mediated mainly by cross-reactivity at GLP-1R [12]. We 
consider it unlikely that the lower blood glucose levels with SRB103Q 
resulted from decreased hepatic glucose output via the subtly reduced 
efficacy of this peptide at GCGR, as it retained full cAMP activity in 
mouse hepatocytes (and in fact showed progressively greater GCGR-
mediated cAMP responses in the Huh7-GCGR model after prolonged 
stimulation), and the observed glycaemic effects were related mainly 
to the ability to restrain the hyperglycaemic effect of exogenously 
administered glucose. For similar reasons, it is improbable that 
reduced GCGR coupling to Gai with SRB103Q is the primary reason for 
its advantageous glycaemic effects, although this remains an outside 
possibility given the recent observation that GCGR-mediated hepatic 
glucose output is paradoxically increased by Gai-dependent JNK 
activation [53]. Nevertheless, further studies into possible effects of MOLECULAR METABOLISM 51 (2021) 101242  2021 The Authors. Published by Elsevier G14 biased or partial agonism at GCGR are warranted and could include 
studies of lipid metabolism, amino acids, energy expenditure, and 
more. As antagonists for GLP-1R and GCGR are generally unable to 
cleanly and completely inhibit the action of high-affinity exogenously 
administered agonists at pharmacological doses, studies of GLP-1R 
and GCGR knockout mice will be needed to distinguish each re-
ceptor’s relative contributions. The well-known phenotype of GCGR 
knockout mice, which are highly resistant to hyperglycaemia and 
show other metabolic abnormalities [76], may introduce additional 
challenges. 
SRB103Q and SRB103H were compared in a chronic administration 
study with liraglutide also included for reference as an exemplar GLP-1R 
mono-agonist. The important observation was that the enhanced anti-
hyperglycaemic benefits of SRB103Q were retained after 2 weeks of 
repeated administration, suggesting that the apparent benefits of its 
intracellular signalling profile on glucose homeostasis did not diminish 
with time. To the best of our knowledge, this represents the first 
demonstration of the possibility of achieving more effective metabolic 
control through partial agonism in the context of a GLP-1R/GCGR co-
agonist. Notably, somewhat greater weight loss without a corresponding 
reduction in food intake for SRB103Q was observed, which could 
conceivably have resulted from increases in sustained GCGR activation 
as might be predicted from the reduced b-arrestin-2 recruitment effi-
cacy of this peptide compared to SRB103H. The glycaemic effects of 
both molecules compared favourably with liraglutide at the same dose, 
although differences in the pharmacokinetics (longer with liraglutide) 
and amount of bioactive free peptide (lower with liraglutide due to mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 
www.molecularmetabolism.com 
albumin binding) complicated interpretation. Nevertheless, the obser-
vation that both SRB103 peptides achieved similar weight loss to lir-
aglutide despite a less potent anorectic effect adds to the evidence that 
GLP-1R/GCGR co-agonism may be an effective method of treating 
obesity, potentially with reduced anorexia-associated nausea (although 
this was not tested directly in our study). 
Darbalaei et al.‘s recent study provided a comprehensive description of 
the pharmacology of other published GLP-1R/GCGR co-agonists [22], 
including two ligands for which clinical data are available: cotadutide 
(MEDI0382) [8] and SAR425899 [77]. Neither of these clinical candi-
date molecules include AIB2 at position 2, but both showed reduced 
recruitment of b-arrestin-2 to GLP-1R, albeit the reduction was not as 
great as for SRB103Q. Both also showed significantly reduced 
recruitment of b-arrestin-2 to GCGR compared to glucagon, a differ-
ence that was larger than GCGR efficacy reduction seen with SRB103Q 
compared to SRB103H. Thus, cotadutide and SAR425899 may well be 
additional examples of incretin receptor ligands retrospectively iden-
tified as showing biased agonist properties as was recently found for 
the dual GLP-1R/GIPR agonist tirzepatide [54,78,79]. However, the 
recorded cAMP potencies for cotadutide and SAR425899 in Darbalaei 
et al.‘s study relative to the endogenous comparator ligands were 
orders of magnitude less than previously reported [77,80], raising the 
possibility that the cellular systems used to evaluate these ligands’ 
pharmacology could have affected the results. 
In conclusion, our study should be seen as an evaluation of the potential 
for reduced efficacy to be incorporated into the assessment process for 
candidate dual GLP-1R/GCGR agonists. Further molecular optimisa-
tions, for example, acylation for extended pharmacokinetics, will be 
required to generate viable molecules for eventual clinical use. Mo-
lecular dynamics simulations indicated the relevant differences in 
engagement with ECL2 and ECL3 that can be used to guide these 
optimisations. Detailed mechanistic research is also needed to establish 
the relative contributions of G protein- and b-arrestin-mediated effects 
at both GLP-1R and GCGR and will help clarify how investigational 
incretin receptor agonists are prioritised during drug development for 
T2D and obesity. 
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